News Today LinesToday's news releases

Press Release · U.S. FDA

FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer

Distributed by News Today Lines · Originally issued via U.S. FDA

For Immediate Release: November 17, 2026

The U.S. Food and Drug Administration today approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile-onset NPC.

“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas, J.D. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”

Niemann-Pick disease type C (NPC) is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells. Over time, these substances accumulate — particularly in the brain — causing progressive neurological decline, including loss of movement, coordination, and the ability to swallow. Patients whose neurological symptoms begin before age 6 face the most serious form of the disease.

Prior to this approval action, two therapies were approved for NPC, but neither has been shown to reduce the risk of death. Both carry age and weight restrictions that limit access for the youngest and most seriously affected patients. Lembaz is the first FDA-approved therapy to reduce the risk of death in adults and children weighing at least 7 kg (about 15 pounds) with NPC whose neurological symptoms began before age 6. A trained healthcare provider gives Lembaz as an injection directly into the spinal canal — a procedure called an intrathecal injection — every two weeks.

To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program. All patients had neurological manifestations of NPC that occurred prior to age 6. Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group. This survival benefit was observed regardless of whether patients were also taking miglustat, a therapy used off-label in NPC.

The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. A comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations.

Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.

Media:
FDA Request for Comment
202-690-6343

Consumer:
888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.